花旗首评看多Dianthus Therapeutics并给出156美元目标价

Citi on Friday issued a new Buy rating on Dianthus Therapeutics ( DNTH ), a biotech developing drugs for autoimmune conditions, citing a multibillion-dollar peak sales opportunity for its lead candidate, claseprubart. The New York-based Dianthus is developing the complement inhibitor as a pipeline-in-a-product targeting a range of autoimmune disorders, including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. Analyst Samantha Semenkow projected more than $5B in peak adjusted global sales for Claseprubart, noting that the drug has already established a competitive efficacy profile thanks to proof-of-concept data in gMG and CIDP. The analyst issued a $156 per share target on the stock, projecting ~$2.5B and $2.4B in peak U.S. unadjusted revenue for claseprubart in gMG and CIDP, respectively. “Given claseprubart’s efficacious, safe, and convenient dosing profile, we see potential for broad uptake both as a best-in-class complement inhibitor and more broadly as a first-line or preferred second-line biologic,” Semenkow wrote. She added that with its two next-gen, dual-mechanism candidates, DNTH212 and DNTH312, the company is broadening its autoimmune franchise into rheumatology and other areas, which give it “longer-term optionality for continued growth.”